HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $61
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor maintains a 'Buy' rating on Halozyme Therapeutics (NASDAQ:HALO) and raises the price target from $60 to $61.
October 19, 2023 | 10:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Halozyme Therapeutics' price target has been raised from $60 to $61 by HC Wainwright & Co. The firm maintains a 'Buy' rating on the stock.
The raised price target and maintained 'Buy' rating by HC Wainwright & Co. indicates a positive outlook for Halozyme Therapeutics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100